Using preferred supplier lists in contract research organisations is common, but reviewing them can be a huge oversight. I delve into what I've learnt from my time in the industry in some more detail.
Alongside the growing trend of value-based searches, I wanted to delve into why candidates prioritise companies that focus on fundamental principles and ethics which resonate with them, as opposed to other more material benefits. Find out why, here.
In this episode, Jack speaks with two Co-Founders at Centivax about life as successful entrepreneurs, the journey to acquisition, challenges and learnings - and using them to become an industry-defining author. Listen now.
AI is revolutionising the world of CRO development and clinical trials - but what are the main benefits of adopting the tech? In this article we explore them, with the help of experts working in the space.
In this episode, Jack speaks with Twlya Tiongson Neal, Managing Director at Accenture, about commercial strategy and what this really looks like in the current life science landscape. Click to listen.
There's no denying the power of LinkedIn as a professional seeking a new role. Try these free tools and tips to ensure you're getting the most out of your search.
Featuring Synda Clements, Director of Talent Acquisition at ConcertAI.
Talent scarcity is hard to solve in the current climate, but developing a strategy of substance for attracting top-tier candidates is the ultimate way to stand out and win the right people. Here, I delve into how to do just that.
.jpg)
In this episode, I speak to Leigh Fell, CEO at Caritas Neuro Solutions, about carving your niche, the impact of work-life balance, the importance of psychedelic drug discovery and loads more. Click here to listen.
How can we improve diversity and access within the research space, particularly at site level? We asked some site managers in the know.
Are you attracting the very best industry talent to your start-up? For expert advice on how to thrive in today’s life science talent market, watch CM Life Science's latest 30-minute webinar. Click to watch.
We spoke to Margaret, Chris, Tiffany and Brad about the challenge clinical trials have in becoming more heterogeneous
Alongside COVID, most sponsors saw a significant shift to a more patient-centric approach in 'decentralized clinical trials'. But what does this mean for the future industry? Click to read more.
We talk to Tim Roberts, who’s Chief Commercial Officer at PCI Pharma Services. Click to listen to his experiences in and predictions for the clinical trial supply market.
What are organisations doing to improve diversity in clinical trials? Click to find out what a panel of CRO leaders had to say in our latest live webinar. Now available as a podcast.
While our industry has continued to raise awareness about the lack of diversity within clinical trials, actually addressing the issue remains our biggest challenge. Click to read how some leaders are addressing this.
.jpg)
In this episode of CM Conversations, our guest share his tips on hitting the ground running and building a team remotely, as well as the importance of investing in relationships. In his words, you should always be visible and available.
In this clip, I talk about how acting fast is crucial to securing the very best talent in life sciences.
.jpg)
In this clip, I discuss the skills and people that are in demand within the life science industry.
.jpg)
In this clip, I talk about how small companies can beat the larger corporations for talent. They just need to show off what makes them different, that they're people-focused and they can be flexible.
In this live episode, join life science recruitment experts Eleanor Doolin and Adam Butler as they discuss how the best businesses from across the life science space are winning the war for talent.
Special purpose acquisition companies, or SPACs, have recently emerged onto the investment scene at a rapid rate. They are an unconventional means of taking a company public but becoming increasingly popular. Are SPACs really here to stay?
Every industry ground to a halt in March 2020 as COVID-19 swept the world. While some sectors were forced to shut down completely, clinical trial providers couldn’t simply stop. That would have meant years of research and funding gone to waste.
Innovative companies are trying to make a real difference for patients with rare diseases and address one of healthcare's largest unmet needs.
.jpg)
There’s optimism throughout all the markets we serve and to celebrate this we asked our CM Life Science team what they think we can expect from the year ahead in life sciences. Here's what they said...
COVID-19 has changed clinical trials forever. To find out how CROs have adapted to the global pandemic and whether this will have a lasting impact on the space, I spoke to two industry leaders.
We are undergoing the biggest vaccination program in history, aiming to finally bring the COVID-19 pandemic to an end. This presents pharmacovigilance’s with its biggest test yet.
.jpg)
With such a strong 2019, 2020 was expected to be a ‘mega year’ for life science companies with a reported $1.4 trillion in firepower at their disposal for M&As. However, COVID-19 gave us an unexpected twist.
For this episode of CM Conversations, our Director of Operations Tom Maskill spoke with QIAGEN CEO Thierry Bernard.
Prejudice is rife in 2020 (both conscious and unconscious), so it’s crucial that we educate ourselves. It’s never been so important to embrace Black History Month.
.jpg)
The effect of COVID-19 has been huge with thousands of clinical trials interrupted forcing companies and sponsors to adapt. So, they have and the industry may never look the same again.
.jpg)
Only 30% of executive positions and 18% of board seats are held by women in biotech. I spoke to an industry expert, Melissa Gammell, to find out where we're going wrong, how we get more women into biotech and how we keep them there.
In this episode of CM Conversations, our lab equipment specialist Lucy Smith spoke with Melissa Gammell, Vice President of Business Development at Matphil Technologies about the challenges facing women in biotech.
.jpg)
In this episode, our specialist in the lab equipment space, Lucy Smith, spoke with CEO of Elementar Americas Ryan Titmas. Lucy spoke to Ryan about what it takes to get to the top, as well as some of the lessons he’s learned in his career so far.
As businesses prioritise the wellbeing of their employees, the concept of working a 4 day week is shifting from distant pipedream to reality for a range of organisations around the world.
Even if you’ve been through the process, you may not be aware of exactly what goes into M&A deals. Today, we’ve tried to look into that in a little more detail with Transaction Liability Team Leader Grant Hollis from CFC Underwriting,
Coronavirus has provided us with a very large and extremely recent data set for research, patient populations and how different ethnic minorities are being affected versus the research. And the early indicators are that those from minority background
The approach to fighting coronavirus has not differed to the fight against any other outbreak in terms of what is required to control it.
One of the biggest partnering events in the life science calendar Bio-Europe Spring, was scheduled to take place in Paris from March 23 – 27 this year. That all changed with the emergence of COVID-19...
.png)
Decentralised, virtual, home, remote… whatever the name of this type of trial, it's widely agreed they will be crucial to advancing healthcare.
I’ve lost count of the times I’ve seen ‘PhD preferred’, while recruiting for positions in R&D and product development. In the modern life science talent market, are PhDs really so important?
I’ve lost count of the times I’ve seen ‘PhD preferred’, while recruiting for positions in R&D and product development. In the modern life science talent market, are PhDs really so important?
In today's hyper-connected world, what's the point of conferences? Our Associate Director Jack Shute asked experts from across the speciality chemical space and some of his CM Life Science colleagues to find out.
If one of the global pharma giants develops a new blockbuster drug, they can’t just ship it. They need to perform extensive testing.
When I first made the decision to write an article about CRO size and what impact it has on service, the idea revolved around a ‘David vs Goliath’ narrative. I was going to write about major CROs compared to smaller CROs, then (spoiler alert) come...
There are a lot of people and organisations who rank Contract/Clinical Research Organisations. Not only that, but they do it extremely well. That’s why the tables and rankings that appear so regularly on our newsfeeds are so popular.
